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Abstract 21 
Purpose: To determine the efficacy of real-time PCR for the diagnosis and prognosis 22 
of varicella-zoster virus (VZV) keratitis. 23 
Study design: Retrospective case series. 24 
Methods: Patients: 545 consecutive patients with keratitis were examined to quantify 25 
copy numbers of VZV DNA by real-time PCR. Association of copy numbers of DNA of 26 
VZV to clinical signs and disease course was assessed using logistic regression 27 
analysis and Cox proportional hazard model. 28 
Results: Of the 545 eyes, 38 eyes (6.9%) were diagnosed as VZV keratitis. The copy 29 
numbers of the DNA of VZV (median: 104.19 copy) was significantly associated with 30 
diagnosis of VZV keratitis with the highest odds ratio (OR) of 3390 (for median copy) 31 
compared to clinical signs. Diagnostic accuracy of the VZV DNA copy indicated good 32 
diagnostic value of area under the curve (0.92) by receiver operating characteristic 33 
analysis, and detection of unrelated VZV DNA from the cornea was very rare (0.2%).  34 
When the VZV DNA copy and clinical signs were assessed for association with the 35 
disease course after herpes zoster ophthalmicus, the disease duration was 36 
significantly prolonged in VZV keratitis cases with higher numbers of VZV DNA copies, 37 
iritis, and history of recurrences. The amount of VZV DNA led to a continuous risk to 38 
prolong disease duration until the ocular inflammation subsides (hazard ratio (HR) 39 
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0.17, 95%CI: 0.07 - 0.42, for median copies). 40 
Conclusions: Higher VZV DNA copy numbers are associated with the refractoriness 41 
of VZV keratitis, and its evaluation may be a clinically useful way to diagnose and 42 
manage VZV keratitis. 43 
 44 
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 51 
Introduction 52 
Herpes zoster contributes significantly to morbidity in elderly individuals and is mainly 53 
caused by a reactivation of the varicella-zoster virus (VZV). Almost one-third of 54 
individuals are estimated to be affected by herpes zoster, [1, 2] and up to 20% of 55 
herpes zoster infections are expressed as herpes zoster ophthalmicus (HZO).[2, 3] 56 
Patients with HZO have significantly higher risks of strokes and post-herpetic 57 
neuralgia. [4-6] Importantly, an ocular complication is observed in 35.1% to 65% of 58 
HZO patients.[7, 8]  59 
 60 
However, the etiology of the ocular complication has not been determined. For 61 
example, the VZV DNA in the ocular lesions of VZV keratitis is occasionally not 62 
detected by conventional PCR. [9] For VZV keratitis cases positive for VZV DNA after 63 
HZO, VZV DNA was believed to disappear soon after the onset. Thus, it is still unclear 64 
whether active keratitis lesions are caused by VZV replication or an inflammatory 65 
response of the host.  66 
 67 
The purpose of this study was to determine the relationship between the presence of 68 
VZV DNA in the eye and the diagnosis of HZO. To accomplish this, we quantified the 69 
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VZV DNA by quantitative real-time PCR (qPCR) and assessed the association of the 70 
copy numbers with the clinical signs with and without previous HZO. We then 71 
analyzed course of ocular complications after HZO. We shall show that VZV DNA was 72 
a significant risk factor for prolonged ocular complications after HZO. 73 
 74 
 75 
Materials and Methods 76 
Patients eligibility and diagnostic criteria of VZV keratitis 77 
The medical records of 545 consecutive cases with clinically diagnosed keratitis were 78 
reviewed, and all were examined at the Tottori University Medical Hospital between 79 
November 2005 and September 2016. All of these cases had undergone qPCR for 80 
VZV. Of these 545 cases, 283 patients were men, and the mean age was 56.1 ± 23.1 81 
years.  82 
 83 
The diagnosis of HZO was based on the presence of primary skin rashes with 84 
erythema within the ophthalmic dermatome as described in detail.[9] Acute VZV 85 
keratitis was diagnosed when keratitis was present with preceding skin rashes <90 86 
days from the onset of the skin lesions.[2] In cases without preceding skin rash with 87 
positive VZV by conventional PCR, a diagnosis of acute VZV keratitis was made by 88 
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the responsiveness to oral valaciclovir/acyclovir or topical acyclovir ointment, or the 89 
combination of these anti-herpetic drugs and steroid treatments. Chronic VZV 90 
keratitis was defined to be present when the activity required anti-viral drugs or 91 
steroids for ≥90 days from the onset of skin lesions.[2] Recurrent disease was defined 92 
to be present, when keratitis recurred ≥90 days after the resolution of the signs 93 
without the use of anti-viral drugs or steroids. DNA samples were collected at each 94 
outpatient visit until the clinical symptoms were resolved for the VZV keratitis cases. 95 
 96 
A diagnosis of herpetic keratitis was made when herpes simplex virus (HSV) was 97 
detected by PCR. A diagnosis of other non-VZV keratitis, including bacterial keratitis, 98 
fungal keratitis, acanthamoeba keratitis, adenoviral keratitis, or autoimmune keratitis, 99 
was made by conventional culturing, smearing, and PCR as described.[10-13]  100 
 101 
This study was approved by the Institutional Review Board of Tottori University, 102 
Faculty of Medicine, Tottori, Japan. An informed consent was obtained prior to the 103 
procedures from all of the participants after an explanation of the procedures to be 104 
used. 105 
 106 
Quantitative real-time PCR 107 
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Samples were collected from the ocular surface and cornea by rinsing them with 400 108 
μl of saline without touching the eyelids and skin lesions. DNA was extracted from the 109 
samples with the QIAamp DNA mini kit (Qiagen, Hilden, Germany) and were 110 
amplified with the LightCycler (Roche, Basel, Switzerland) using QuantiTect Probe 111 
PCR kit (Qiagen) and primers (Supplementary Table 1).[14, 15] To determine the 112 
copy numbers of the DNA of VZV, a standard curve was generated with serial 113 
dilutions of synthesized DNA fragments of the VZV polymerase gene.[14] The limit of 114 
detection at a 95% detection probability was 49 copies/assay. VZV copy number was 115 
adjusted by measurement of human GAPDH copy. [15] 116 
 117 
Statistical analyses 118 
Data are presented as the means ± standard deviations (SDs). For bilateral cases, 119 
the more severely affected eye was used for the statistical analyses. Cox proportional 120 
hazard model with shared frailty was used to calculate the hazard ratio (HR) during 121 
the course of the disease. Statistical analyses were conducted using Stata 14. A P 122 
<0.05 was considered significant.  123 
 124 
Results 125 
Diagnostic efficacy of qPCR for VZV keratitis 126 
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Patients with corneal ulcer or inflammatory keratitis which was suspected to be 127 
caused by VZV infection or required the exclusion of VZV for diagnosis were studied. 128 
Of the 545 eyes, 38 eyes (6.9%) were diagnosed with VZV keratitis. Thirty-seven 129 
eyes had HZO keratitis and 1 eye had varicella keratitis. The mean age of the HZO 130 
keratitis patients was 63.2 ± 20.0 years (Table 1).  131 
 132 
qPCR for VZV was positive for 32 eyes (5.9%) of all the cases, and 30 eyes of PCR 133 
positive cases had HZO keratitis and 1 eye had varicella keratitis. All the VZV keratitis 134 
cases had prior periocular skin rashes, and 35 eyes (92.1%) were within 3 months of 135 
the initial visit. The percentage of eyes with ocular shedding of VZV DNA by non-VZV 136 
infection was very low in the diseased corneas (0.2%). 137 
 138 
For the eyes diagnosed with VZV keratitis, the mean copy number was 104.21 ± 102.61, 139 
and the median copy number was 104.19. VZV DNA was significantly associated with 140 
VZV keratitis (Odds ratio (OR): 3390 for 104.19 (median) copies, 6.9/log copy, after 141 
age and GAPDH adjustments, P = 0.000; Table 2). Periocular skin rashes 142 
(irrespective of dermatomal distribution and within the prior 3 months) also 143 
significantly associated with VZV keratitis, followed by ocular hypertension, iritis with 144 
mutton fat keratic precipitates, dendritic lesions, and scleritis (Table 2).  145 
 146 
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Next, we determined how these clinical signs and VZV DNA copy numbers are 147 
related to the diagnosis of VZV keratitis (Table 2). VZV DNA qPCR had a sensitivity of 148 
81.6% and specificity of 99.8%. The likelihood ratio, which denotes the efficiency of 149 
the test, was the highest at 408 (Table 2). In contrast to the clinical signs, qPCR for 150 
VZV had higher positive predictive value and likelihood ratio, indicating that qPCR is 151 
accurate for both the negative and positive results for the diagnosis of VZV keratitis. 152 
 153 
Of the 545 eyes, periocular skin rashes were observed in 49 eyes (9.0%), and 15 of 154 
these eyes (30.6%) were not related to VZV infection. The sensitivity and specificity of 155 
the skin rashes was 92.1% and 97.2%, and its likelihood ratio was lower at 32.9.  156 
 157 
Other clinical signs, including ocular hypertension, iritis, corneal dendritic lesion, and 158 
scleritis, were also significantly associated with VZV keratitis, however, lower in 159 
positive predictive value and likelihood ratio.  160 
 161 
Next, we assessed the diagnostic accuracy of these signs in comparison to that of 162 
qPCR using receiver operating characteristic analysis (ROC; Figure 1). The area 163 
under the curve (AUC) for periocular skin rashes calculated as reference was 0.95 164 
(95%CI: 0.90 – 0.99). The AUC for VZV qPCR was 0.92 (95%CI: 0.86 – 0.98) after 165 
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GAPDH adjustments and was not different for the skin rashes. The AUC of dendritic 166 
lesions, ocular hypertension, and iritis was 0.66 (95%CI: 0.58 – 0.74), 0.62 (95%CI: 167 
0.55 -0.70), and 0.60 (95%CI: 0.53 – 0.67) respectively, and their diagnostic accuracy 168 
was significantly lower than that of qPCR (P =0.000).  169 
 170 
Association of copy numbers of DNA of VZV to clinical signs and disease 171 
course 172 
We determined whether the copy numbers of the DNA of VZV was significantly 173 
associated with the clinical signs or outcomes using logistic regression analysis 174 
(Table 3). As expected, the copy number of DNA at the first visit was significantly 175 
associated with the presence of periocular skin rashes (OR: 100.6 for median copies, 176 
95% CI: 22.9-441.9, P = 0.000, age and GAPDH adjusted). Notably, the copy number 177 
of DNA was significantly associated with iritis with OR of 6.0 indicating that high VZV 178 
copy number is especially associated with intraocular inflammation. This was 179 
followed by ocular hypertension (OR: 3.7) and dendritic lesion (OR: 3.5).  180 
 181 
 182 
Therefore, we determined whether the amount of the DNA of VZV at the initial 183 
diagnosis of keratitis can predict the refractoriness and prognosis of HZO keratitis. A 184 
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higher copy number of VZV DNA at the first visit was significantly correlated with the 185 
duration of the disease (ρ = 0.53, P = 0.0007, Spearman correlation analysis). In 186 
refractory cases with iritis as the intraocular inflammation, the VZV genome was 187 
detected until all clinical signs of the keratitis were not detected (Figure 2).  188 
 189 
When the history of recurrences was evaluated in HZO keratitis patients, 8 eyes 190 
(21.6%) had a history of recurrences. Of these 8 eyes, 2 eyes (25%) were from 191 
immune compromised patients. Immune compromised patients had significantly 192 
higher number of recurrences by a 50.6% increase of chance (P = 0.019 after VZV 193 
DNA copy adjustment).  194 
 195 
The mean duration of the HZO keratitis was 119 days (95%CI: 82 – 155). Kaplan 196 
Meier survival analyses were performed to determine whether high copy numbers 197 
(more than the median) at the first visit, the clinical characteristics and previous 198 
recurrences were associated with the disease duration. The results showed that high 199 
VZV copy numbers (≥median; P = 0.008, log-rank test), iritis (P = 0.01), and history of 200 
recurrences were significantly associated with the duration of the disease (P = 0.006, 201 
Figure 3). Importantly, iritis with high VZV copy number had the most significant effect 202 
on the disease duration. 203 
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 204 
During the course of the disease process, we monitored the copy numbers of the 205 
DNA of VZV until HZO keratitis resolved. DNA of VZV was continuously detected at 206 
the outpatient visits with declining tendency, and become detectable when signs 207 
become absent. Then, we calculated the hazard ratio of VZV copy numbers during 208 
the course (including the first visit) on the disease duration. VZV copy numbers 209 
indicated highly significant HR, and was 0.17 for median of VZV copies (95% CI: 210 
0.07- 0.42, P =0.000). Thus, detection of VZV copy number predicted a prolonged 211 
disease course, and the disease prolonging effect declines with its decrease and 212 
become negligible when it is not detected. HR indicated that the keratitis was six 213 
times more likely not to be resolved on a given date when the VZV copy numbers 214 
exceeded median. Presence of iritis were also significant risk factor associated with 215 
longer disease duration with comparable HR (HR, 0.14, 95% CI: 0.04- 0.49, P = 216 
0.002). When the history of recurrences was assessed, the hazard ratio was 217 
calculated to be 0.15 (95%CI: 0.03 – 0.69, P = 0.01), indicating that recurrences were 218 
also associated significantly with a prolongation of the disease duration. 219 
 220 
 221 
 222 
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Discussion 223 
Our results showed that qPCR is highly efficacious for diagnosing ocular VZV 224 
infection. Using qPCR, we here show two important findings. First, in case of high 225 
viral loads at ocular surface after HZO, the prolongation of keratitis was significantly 226 
associated with continuous viral production. Second, VZV keratitis was strictly 227 
associated with previous HZO, although VZV iritis without keratitis can often occur 228 
without noticeable history of HZO. These information is important for the 229 
management of refractory ocular complications after HZO because ocular 230 
inflammation was previously thought to be an anti-viral immune response without viral 231 
production and often treated without antiviral medications. 232 
 233 
Zaal et al examined the inflammation of VZV keratitis after HZO by conventional 234 
PCR.[9] Because the inflammation often persisted after the VZV genome became 235 
undetectable, they suggested that inflammation was an important component of the 236 
pathology of VZV keratitis. 237 
 238 
Considering the inflammatory aspect of ocular complications after HZO, a 239 
combination of antiviral drugs and steroids is generally used, however consensus has 240 
not been reached on how antiviral agents should be used. [16] The general belief was 241 
15 
 
that the period of VZV replication in the lesion is not prolonged beyond the acute 242 
phase of skin lesion stage. Currently, one-third of corneal specialists use antiviral 243 
drugs for 2 weeks and 18% do not use antivirals for HZO.[16]  244 
 245 
In chronic and refractory cases, high amounts of VZV DNA were detected for a long 246 
time. If antivirals are discontinued after presumed clinical remission with significant 247 
viral replication, a recurrence in the form of delayed dendritic ulcer or iritis develops 248 
as ocular complications can be expected. Thus, VZV qPCR will be beneficial for 249 
clinicians to optimize drug dosage and duration during the disease course when the 250 
signs are resolving.  251 
 252 
The presence of iritis was recently shown to be significantly associated with a risk of 253 
recurrences or chronicity in VZV keratitis after HZO.[2] We found that iritis with low 254 
copy numbers of the DNA of VZV was not a significant risk factor for refractoriness 255 
(Figure 2a). Instead, a combination of high amounts of VZV DNA copy and iritis were 256 
the most significant factors in the refractory cases. In the refractory or chronic cases, 257 
high VZV DNA copy numbers were maintained until the inflammation subsided. This 258 
suggests that prolonged viral replication and not the presence of iritis, determines the 259 
disease course in refractory cases.  260 
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 261 
The results of two studies have suggested that the detection of VZV may be caused 262 
by shedding and was independent of the refractoriness.[8, 17] In addition, VZV may 263 
be often reactivated in the saliva of healthy individuals when under extreme 264 
stress.[17] In bone marrow transplant patients, 19% have subclinical viremia without 265 
signs of HZO.[3, 18] This suggested detection of viral genome was frequent, and may 266 
not reflect diseases. In Japanese population, seropositivity reaches almost 100% in 267 
elderly subjects. [19]   However, we found that the rate of unrelated VZV shedding 268 
from the eye was very low (0.2%) even in eyes stressed by non-VZV keratitis. This is 269 
in marked contrast to ocular HSV infection, in which spontaneous HSV shedding in 270 
tear is observed in one third of healthy subjects. [20] 271 
 272 
Recurrences of ocular complication after HZO are frequent. The percentage of eyes 273 
with recurrences range between 5 to 25% depending on the duration of the 274 
observation period.[2, 21, 22] Consistent with previous reports, the recurrence 275 
percentage in our study was 21.6%. Tran et al reported that a recurrence of keratitis 276 
after HZO was associated with uveitis and ocular hypertension.[2] However, we could 277 
not confirm any significant associations of the recurrences with these clinical signs or 278 
the VZV DNA copy numbers. Instead, we found that the disease duration of single 279 
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episode was the only significant risk factor for recurrences. We suggest that the 280 
clinical signs are secondary to the long disease course which would directly explain 281 
the recurrences. 282 
 283 
There are several limitations in our study. Our data were obtained at a tertiary referral 284 
institution, and selection or referral bias may have affected our outcomes. However, 285 
our data are based on 12 consecutive years of observation and should provide 286 
epidemiological evidence for Asians. In addition, the outcomes from a large series of 287 
VZV qPCR data from the eye have not been available. 288 
 289 
In conclusion, VZV qPCR revealed an unexpectedly longer viral replication period 290 
and provided an effective measure to assess the viral load accurately during the 291 
course of the disease process. We propose that the management strategy of ocular 292 
complication after HZO would be significantly improved in the future with the use of 293 
VZV qPCR. 294 
 295 
  296 
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 367 
Table 1  Demographic information of patients and VZV keratitis 
Total 545 eyes HZO keratitis 
N=37 
Varicella keratitis 
N=1 
Non-VZV-associated keratitis 
N=507 
Age 63.2 ± 20.0 2 55.7 ± 23.1 
Male 24 eyes  
(64.9%) 
0 eyes 259 eyes  
(51.1%) 
Asthma 3 eyes  
(8.1%) 
0 eyes 11 eyes  
(2.2%) 
Eczema 1 eyes  
(2.7%) 
1 eyes 31 eyes  
(6.1%) 
 368 
  369 
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 370 
Table 2  Association of VZV DNA copy numbers and clinical signs of VZV keratitis and evaluation of 
their diagnostic accuracy 
Total 545 eyes ratio of 
positive 
eyes 
Odds ratio 
after age 
adjustment  
positive 
predictive 
value 
negative 
predictive 
value 
Sensitivity 
 
Specificity 
 
likelihood 
ratio 
 
 
VZV DNA 
copy 
 
 
32*  
(5.9%) 
3390*  
(135-85383)  
:median copy 
 
 
96.9% 
(80.3-99.6%) 
 
 
98.6% 
(97.2-99.3%) 
 
 
81.6% 
(65.8-91.1%) 
 
 
99.8% 
(98.6-100%) 
 
 
408 
(47-3037) 6.9*  
(3.2-15.0) 
:log copy 
Periocular 
skin rashes 
49 *  
(9.0%) 
701*  
(162 - 3057) 
71.4% 
(57.2-82.4%) 
99.4% 
(98.1-99.8%) 
92.1% 
(77.9-97.5%) 
97.2% 
(95.3-98.3%) 
32.9 
(16.6-57.4) 
Ocular 
hypertension 
47* 
(8.6%) 
5.8*  
(2.7 – 12.6) 
25.5% 
(15.0-40.0%) 
94.8% 
(92.4-96.4%) 
31.6% 
(18.7-48.0%) 
93.1% 
(90.5-95.0%) 
4.6 
(2.0-9.6) 
Iritis with 
mutton fat 
keratic 
precipitates 
 
39*  
(7.2%) 
 
5.4*  
(2.4 - 12.5) 
 
25.6% 
(14.3-41.7%) 
 
94.5% 
(92.1-96.2%) 
 
26.3 
(14.6-42.6%) 
 
94.3% 
(91.9-96.0%) 
 
4.6 
(1.8-10.7) 
 
Corneal 
dendritic 
lesion 
85*  
(15.6%) 
5.0*  
(2.5 - 10.1) 
20.0% 
(12.8-30.0%) 
95.4% 
(93.1-97.0%) 
44.7% 
(29.7-60.8%) 
86.6% 
(83.3%-89.3%) 
3.3 
(1.8-5.7) 
Scleritis 28** 
(5.1%) 
3.9 *** 
(1.5 – 10.4) 
21.4% 
(9.8-40.7%) 
93.8% 
(91.4-95.6%) 
15.8% 
(7.2-31.3%) 
95.7% 
(93.5-97.1%) 
3.7 
(1.1-10.8) 
*: statistically significant, *: P=0.000, **: P=0.009, ***: P=0.006, 95% confidence interval (95%CI) 
 371 
  372 
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 373 
Table 3  Association of VZV copy numbers to clinical signs and characteristics 
 Odds ratio 
 (Median copy) 
95% confidence interval P value 
Periocular skin rashes 100.6 22.9 – 441.9 0.000 
Iritis (with mutton fat keratic precipitates) 6.0 2.4 – 15.2 0.000 
Ocular hypertension 3.7 1.6 - 8.9 0.003 
Corneal dendritic lesion 3.5 1.6 – 7.9 0.002 
Logistic regression analysis after age and GAPDH adjustment 
 374 
  375 
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 376 
Figure captions 377 
Figure 1. Diagnostic accuracy of qPCR for VZV and clinical signs. 378 
The sensitivity and specificity of VZV qPCR and clinical signs to diagnose VZV 379 
keratitis are plotted to determine the area under the curve (AUC) as diagnostic 380 
accuracy by receiver operating characteristic analysis. The VZV DNA copy number 381 
has a very high accuracy comparable to that for skin rashes calculated as reference 382 
and is significantly better than the other signs.  383 
 384 
Figure 2. Case of VZV keratitis with duration of VZV disease. A 53-year-old man 385 
presented with herpes zoster ophthalmicus (HZO) with periocular skin rashes. One 386 
month later, he developed VZV keratitis with corneal edema and iritis, and the copy 387 
number of the DNA of VZV was 4.7 ×105. The elevated copy number was present for 388 
4 months.  389 
a VZV keratitis with stromal infiltration (arrow) and iritis with VZV copy of 4.5 ×105 at 2 390 
months after the onset of HZO.  391 
b Prolonged elevation of VZV DNA copy number during the course of the disease.  392 
 393 
Figure 3. Association of duration of VZV keratitis to VZV DNA copy number and 394 
27 
 
clinical characteristics. 395 
Disease duration was analyzed using Kaplan Meier survival analysis and plotted on 396 
non-healing rate. a High VZV DNA copy number (≥median (104.19 copies); P = 0.008, 397 
log-rank test), the presence of iritis (P = 0.01), and b history of recurrences (P = 398 
0.006) were significantly associated with the disease duration. 399 
 400 
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